{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:43:53Z","timestamp":1789494233992,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004240","name":"Akademie V\u011bd \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["LX22NPO5104"],"award-info":[{"award-number":["LX22NPO5104"]}],"id":[{"id":"10.13039\/501100004240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004240","name":"Akademie V\u011bd \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["RVO 67985823"],"award-info":[{"award-number":["RVO 67985823"]}],"id":[{"id":"10.13039\/501100004240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.biopha.2024.116520","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T23:57:13Z","timestamp":1712275033000},"page":"116520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet"],"prefix":"10.1016","volume":"174","author":[{"given":"Silvie","family":"Hojn\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Mal\u00ednsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"H\u00fcttl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zde\u0148ka","family":"Va\u0148ourkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-7636","authenticated-orcid":false,"given":"Irena","family":"Markov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Mikl\u00e1nkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Hrdli\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franti\u0161ek","family":"Papou\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Neck\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kujal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Behuliak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Rauchov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kadlecov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sedmera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"Neffeov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3614-7943","authenticated-orcid":false,"given":"Eva","family":"Z\u00e1brodsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Olejn\u00ed\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Zicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Van\u011b\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2024.116520_bib1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"issue":"15","key":"10.1016\/j.biopha.2024.116520_bib2","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1042\/CS20201017","article-title":"Sex differences in hypertension: lessons from spontaneously hypertensive rats (SHR)","volume":"135","author":"Elmarakby","year":"2021","journal-title":"Clin. Sci. (Lond. )"},{"issue":"9","key":"10.1016\/j.biopha.2024.116520_bib3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/nu9091018","article-title":"Combination of hypertension along with a high fat and cholesterol diet induces severe hepatic inflammation in rats via a signaling network comprising NF-\u03baB, MAPK, and Nrf2 pathways","volume":"9","author":"Yuan","year":"2017","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.biopha.2024.116520_bib4","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1161\/HYPERTENSIONAHA.108.127514","article-title":"Dietary-induced obesity hastens the progression from concentric cardiac hypertrophy to pump dysfunction in spontaneously hypertensive rats","volume":"54","author":"Majane","year":"2009","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116520_bib6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","article-title":"Cellular and molecular pathobiology of heart failure with preserved ejection fraction","volume":"18","author":"Mishra","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116520_bib7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c <7%: results from the CREDENCE trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.biopha.2024.116520_bib8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2024.116520_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116520_bib10","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10254","key":"10.1016\/j.biopha.2024.116520_bib12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib14","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2024.116520_bib15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail"},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-021-01322-6","article-title":"The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats","volume":"20","author":"Daud","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib17","doi-asserted-by":"crossref","first-page":"9544","DOI":"10.1038\/s41598-021-89149-9","article-title":"Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats","volume":"11","author":"Seefeldt","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-020-0994-y","article-title":"Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction","volume":"19","author":"Connelly","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2024.116520_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.116520_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106659","article-title":"Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome","volume":"188","author":"Urbanek","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2024.116520_bib21","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.biopha.2018.10.095","article-title":"Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat","volume":"109","author":"Yang","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib22","article-title":"Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE((-\/-)) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2024.116520_bib24","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.3390\/ijms22126332","article-title":"Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH","volume":"22","author":"Perakakis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.biopha.2024.116520_bib25","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"H\u00fcttl","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2024.116520_bib26","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 Inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116520_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112246","article-title":"I. Van\u011b\u010dkov\u00e1, Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension","volume":"144","author":"Hojn\u00e1","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.116520_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112606","article-title":"Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5\/6 nephrectomised rats on high salt diet","volume":"146","author":"Zeng","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"issue":"7-8","key":"10.1016\/j.biopha.2024.116520_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.nut.2015.03.011","article-title":"Conjugated linoleic acid reduces visceral and ectopic lipid accumulation and insulin resistance in chronic severe hypertriacylglycerolemia","volume":"31","author":"Malinska","year":"2015","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.biopha.2024.116520_bib31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.33549\/physiolres.933308","article-title":"Beneficial effect of continuous normobaric hypoxia on ventricular dilatation in rats with post-infarction heart failure","volume":"65","author":"Hrdli\u010dka","year":"2016","journal-title":"Physiol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.33549\/physiolres.934369","article-title":"Sex differences in blood pressure of aged Ren-2 transgenic rats","volume":"69","author":"Rauchov\u00e1","year":"2020","journal-title":"Physiol. Res."},{"issue":"6","key":"10.1016\/j.biopha.2024.116520_bib33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2024.116520_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1440-1827.2008.02237.x","article-title":"New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progresses to end-stage renal failure","volume":"58","author":"Nakano","year":"2008","journal-title":"Pathol. Int."},{"issue":"5","key":"10.1016\/j.biopha.2024.116520_bib35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/ki.1987.262","article-title":"The enhancement of aminonucleoside nephrosis by the co-administration of protamine","volume":"32","author":"Saito","year":"1987","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.biopha.2024.116520_bib36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1253\/circj.CJ-15-1309","article-title":"Native T1 Relaxation Time and Extracellular Volume Fraction as Accurate Markers of Diffuse Myocardial Fibrosis in Heart Valve Disease\u25a1- Comparison With Targeted Left Ventricular Myocardial Biopsy","volume":"80","author":"Kockova","year":"2016","journal-title":"Circ. J."},{"issue":"7","key":"10.1016\/j.biopha.2024.116520_bib37","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41440-018-0198-y","article-title":"Which sympathoadrenal abnormalities of adult spontaneously hypertensive rats can be traced to a prehypertensive stage?","volume":"42","author":"Vav\u0159\u00ednov\u00e1","year":"2019","journal-title":"Hypertens. Res."},{"issue":"4","key":"10.1016\/j.biopha.2024.116520_bib38","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00386.2021","article-title":"SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet","volume":"322","author":"Reverte","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116520_bib39","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/biomedicines10102509","article-title":"Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease","volume":"10","author":"Hojn\u00e1","year":"2022","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.biopha.2024.116520_bib40","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3390\/biomedicines10092066","article-title":"Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein","volume":"10","author":"Mal\u00ednsk\u00e1","year":"2022","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.biopha.2024.116520_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2019.7923","article-title":"Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress","volume":"34","author":"Nikolaou","year":"2021","journal-title":"Antioxid. Redox Signal"},{"issue":"5","key":"10.1016\/j.biopha.2024.116520_bib42","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1248\/bpb.b16-00964","article-title":"The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats","volume":"40","author":"Takasu","year":"2017","journal-title":"Biol. Pharm. Bull."},{"issue":"3","key":"10.1016\/j.biopha.2024.116520_bib43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10557-020-06954-6","article-title":"Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction","volume":"34","author":"Yurista","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am. J. Nephrol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116520_bib45","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116520_bib46","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/eurjpc\/zwab034","article-title":"Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin","volume":"29","author":"Fontes-Carvalho","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"16","key":"10.1016\/j.biopha.2024.116520_bib47","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.biopha.2024.116520_bib48","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-8587(21)00292-8","article-title":"Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial","volume":"10","author":"Verma","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"19","key":"10.1016\/j.biopha.2024.116520_bib51","doi-asserted-by":"crossref","first-page":"10989","DOI":"10.3390\/ijms231910989","article-title":"Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model","volume":"23","author":"Winzer","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2024.116520_bib52","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1074248418763808","article-title":"Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat","volume":"23","author":"Younis","year":"2018","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/dom.13536","article-title":"Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized (13) C magnetic resonance spectroscopy study","volume":"21","author":"Abdurrachim","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116520_bib55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-020-01208-z","article-title":"Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF","volume":"20","author":"Bode","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116520_bib56","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/10742484211001853","article-title":"A Sodium glucose cotransporter 2 inhibitor fails to improve perivascular adipose tissue-mediated modulation of vasodilation and cardiac function in rats with metabolic syndrome","volume":"26","author":"Kagota","year":"2021","journal-title":"J. Cardiovasc Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2024.116520_bib57","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1248\/bpb.b22-00289","article-title":"The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy","volume":"45","author":"Takasu","year":"2022","journal-title":"Biol. Pharm. Bull."},{"issue":"9","key":"10.1016\/j.biopha.2024.116520_bib58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00210-020-01873-7","article-title":"Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats","volume":"393","author":"Krasnova","year":"2020","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116520_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107095","article-title":"Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2","volume":"146","author":"Bruckert","year":"2022","journal-title":"Vasc. Pharmacol."},{"issue":"23","key":"10.1016\/j.biopha.2024.116520_bib60","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1111\/bph.14931","article-title":"Hyperlipidaemia and cardioprotection: animal models for translational studies","volume":"177","author":"Andreadou","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116520_bib61","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","article-title":"A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer","volume":"65","author":"Asgharpour","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.116520_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol. Cell Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib63","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2024.116520_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2017.05.005","article-title":"Cytochrome P450-derived eicosanoids and heart function","volume":"179","author":"Jamieson","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2024.116520_bib65","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1152\/ajpendo.00366.2014","article-title":"CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice","volume":"308","author":"Chen","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2024.116520_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115289","article-title":"RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor","volume":"166","author":"Tan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.116520_bib67","doi-asserted-by":"crossref","unstructured":"T. Kimura, K. Nakamura, T. Miyoshi, M. Yoshida, K. Akazawa, Y. Saito, S. Akagi, Y. Ohno, M. Kondo, D. Miura, J. Wada, H. Ito H, Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High- Fat Diet, Int Heart J. 60 (3) (2019) 728-735.","DOI":"10.1536\/ihj.18-392"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224004049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224004049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:16:30Z","timestamp":1782342990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224004049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":67,"alternative-id":["S0753332224004049"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116520","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116520","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116520"}}